Home › Research › Treatments
Lecanemab reduces brain amyloid-β and delays cognitive worsening
Knopman DS.. Cell reports. Medicine, 2023-03-01
Topic: Brain proteins, microglia and lab models
Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Knopman, D. S. (2023). Lecanemab reduces brain amyloid-β and delays cognitive worsening. Cell reports. Medicine. https://doi.org/10.1016/j.xcrm.2023.100982
Vancouver
Knopman DS. Lecanemab reduces brain amyloid-β and delays cognitive worsening. Cell reports. Medicine. 2023. doi:10.1016/j.xcrm.2023.100982. PMID: 36948153.
BibTeX
@article{knopman2023-36948153,
author = {Knopman, D. S.},
title = {{Lecanemab reduces brain amyloid-β and delays cognitive worsening}},
journal = {Cell reports. Medicine},
year = {2023},
doi = {10.1016/j.xcrm.2023.100982},
pmid = {36948153},
url = {https://doi.org/10.1016/j.xcrm.2023.100982}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
Why it matters
In an 18-month double-blinded randomized placebo-controlled trial, lecanemab cleared amyloid-β in two-thirds of people with mild cognitive impairment and mild dementia due to Alzheimer disease and reduced the rate of cognitive and functional worsening. This indicates the drug can affect both a brain marker of the disease and the pace of symptom decline in these patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cell reports. Medicine) |
| Journal's citation record | 1 / 4 | Cell Reports Medicine: journal h-index 104 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 30 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David S. Knopman: h-index 188 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36948153) |
| Free to read | 2 / 2 | Free to read |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.xcrm.2023.100982
- PubMed: 36948153
- Original source →
- Free full text: Cell Reports Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.